Greater Access to Affordable Pharmaceuticals Act of 2001
Official title: To amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals.
More subjectsShow fewer subjects
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Sponsor introductory remarks on measure. (CR H2110)
Allows a drug to be considered a bioequivalent to a listed drug if the effects of such drug and the listed drug do not show a significant difference based on certain tests or studies.
Sets forth requirements concerning the filing of a citizen petition review.
Revises provisions concerning: (1) abbreviated new drug applications and new drug applications with respect to the time required for approval and the certification that a patent is invalid or will not be infringed; and (2) filing an application.
Requires a report concerning the extent to which this Act has: (1) has enabled products to come to market in a fair and expeditious manner, consistent with the rights of patent owners under intellectual property law; and (2) has promoted lower prices of drugs and greater access to drugs through price competition..
- Introduced in House Formatted Text PDF
Cite this page
U.S. Congress. (2026). H.R. 1862: Greater Access to Affordable Pharmaceuticals Act of 2001. 107th Congress. Open America. https://openamerica.io/bill/107-HR-1862/
"H.R. 1862: Greater Access to Affordable Pharmaceuticals Act of 2001." 107th Congress, 2026, Open America, https://openamerica.io/bill/107-HR-1862/.
H.R. 1862, 107th Cong. (2026), https://openamerica.io/bill/107-HR-1862/.
[H.R. 1862: Greater Access to Affordable Pharmaceuticals Act of 2001](https://openamerica.io/bill/107-HR-1862/)